Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Frank, Struyf"'
Autor:
Jean-Yves Pirçon, Olivier Gruselle, Raghavendra Devadiga, Frank Struyf, Jeanne-Marie Devaster, Jiří Beran, Thi Lien-Anh Nguyen, Ana Ramirez Villaescusa
Publikováno v:
Central European Journal of Public Health. 29:167-176
Objectives Due to immunosenescence and presence of comorbidities, respiratory syncytial virus (RSV) disease burden is a major health concern in older adults, which is expected to increase with the life expectancy rise. Data on RSV burden are scarce i
Autor:
Jerald, Sadoff, Glenda, Gray, An, Vandebosch, Vicky, Cárdenas, Georgi, Shukarev, Beatriz, Grinsztejn, Paul A, Goepfert, Carla, Truyers, Hein, Fennema, Bart, Spiessens, Kim, Offergeld, Gert, Scheper, Kimberly L, Taylor, Merlin L, Robb, John, Treanor, Dan H, Barouch, Jeffrey, Stoddard, Martin F, Ryser, Mary A, Marovich, Kathleen M, Neuzil, Lawrence, Corey, Nancy, Cauwenberghs, Tamzin, Tanner, Karin, Hardt, Javier, Ruiz-Guiñazú, Mathieu, Le Gars, Hanneke, Schuitemaker, Johan, Van Hoof, Frank, Struyf, Macaya, Douoguih, Marcus, Zervos
Publikováno v:
New England Journal of Medicine. 384:2187-2201
The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation.In an internation
Autor:
Hui Xiao, Xiangbin Lu, Yanqiu Zhang, Zhilong Ma, Frank Struyf, Naveen Karkada, Yabin Xu, Nicolas Folschweiller, Johny Jiang, Yan Xie, Yunyu Jiang, Archana Jastorff, Dorota Borys, Yuemei Hu, Yilin He, Sylviane Poncelet, Xiang Zhang
Publikováno v:
Asia-Pacific Journal of Clinical Oncology
Aim In 9‐17‐year‐old Chinese girls, the AS04‐adjuvanted HPV‐16/18 vaccine (AS04‐HPV‐16/18) given as three‐dose schedule induced high antibody levels, which were noninferior 1 month after the third dose to those observed in 18‐25‐y
Autor:
Kari Natunen, Mari Hokkanen, Tuomas Lehtinen, Frank Struyf, Dan Bi, Tiina Eriksson, Silvia Damaso, Matti Lehtinen, Katja Harjula, Dan Apter, Maaria Soila
Publikováno v:
International Journal of Cancer
We studied effectiveness of the AS04‐adjuvanted HPV‐16/18 (AS04‐HPV‐16/18) vaccine against human papillomavirus (HPV) oropharyngeal infections associated with the increase of head/neck cancers in western countries. All 38,631 resident adolesc
Autor:
Silvia Damaso, Tiina Eriksson, Matti Lehtinen, Dan Bi, Dan Apter, Julia Zima, Mari Hokkanen, Frank Struyf, Gary Dubin, Maaria Soila
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
This manuscript discloses end-of-study safety data of a community-randomized controlled trial in Finland (NCT00534638), assessing the effectiveness of two vaccination strategies (gender-neutral versus females only) using the AS04-adjuvanted human pap
Autor:
Fengcai Zhu, Qin-Jing Pan, Jia-Xi Yu, Frank Struyf, Ying Hong, Yunkun He, Shang-Ying Hu, Naveen Karkada, Yuemei Hu, Yi-Ju Zhang, Yan-Shu Zhang, Xiaoping Yang, Haiwen Tang, Cheng-Fu Zhang, Feng Chen, P.V. Suryakiran, Dan Bi, Jun Bi, Changrong Wang, Fang-Hui Zhao, Xun Zhang, Lingling Shen, Qian Zhang, Hong Wang, Shiyin Xue, Wen-hua Zhang, Jiahong Zhu, Yejiang Zhu
Publikováno v:
Cancer Medicine, Vol 8, Iss 14, Pp 6195-6211 (2019)
Cancer Medicine
Cancer Medicine
Background Cervical cancer is a major public health concern in China. We report the end‐of‐study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the AS04‐human papillomavirus (HPV)‐16/18 vaccine in Chines
Autor:
Maria Mercedes Castrejon Alba, Naveen Karkada, Maria Angelica Granados, Frank Struyf, Albino Salas Cespedes, Adriana Luque, Luis Romano-Mazzotti, Mercedes Macías Parra, Dorota Borys, Victor Y Sierra, Lan Lin
Publikováno v:
The Pediatric Infectious Disease Journal. 38:1061-1067
The burden of human papillomavirus (HPV) diseases is high in Latin America. HPV vaccines licensed from 2006 onwards offer protection against most HPV-related cancers, especially when introduced into national immunization programs. Barriers to optimal
Autor:
Tiina Petäjä, Simopekka Vänskä, Tiina Eriksson, Jorma Paavonen, Matti Lehtinen, Pekka Nieminen, Katja Harjula, Maaria Soila, Eero Pukkala, Frank Struyf, Kari Natunen, Dan Apter, Johanna Palmroth, Mari Hokkanen, Brigitte Cheuvart, Dan Bi
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7759-7771 (2021)
Cancer Medicine
Cancer Medicine
Introduction We conducted a community‐randomized trial (NCTBLINDED) in Finland to assess gender‐neutral and girls‐only vaccination strategies with the AS04‐adjuvanted human papillomavirus (HPV)‐16/18 (AS04‐HPV‐16/18)vaccine. Methods Gir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea8fc63a95f9acc2c6e1d7df61bc7f3b
http://hdl.handle.net/10138/336609
http://hdl.handle.net/10138/336609
Autor:
Catherine Jacob-Dolan, Michael S. Seaman, Carolyn D. Alonso, Macaya Douoguih, Hanneke Schuitemaker, Ruvandhi R. Nathavitharana, Jinyan Liu, Lisa H. Tostanoski, Roger L. Shapiro, Jerald C. Sadoff, Kate Jaegle, Shivani A. Patel, Katherine E. Yanosick, Abishek Chandrashekar, Katherine McMahan, Jessica L Ansel, Chen S. Tan, Dan H. Barouch, Diane G. Kanjilal, Jingyou Yu, Morgana Souza, Douglas A. Lauffenburger, Anna Tyler, Anne Marit de Groot, Caitlin J. Guiney, Frank Struyf, Mathieu Le Gars, Connor Bradshaw, Kathryn E. Stephenson, Joseph P. Nkolola, Carla Truyers, Zhenfeng Li, Rebecca Zash, Boris Julg, Carolin Loos, Caroline Atyeo, Galit Alter, Johan Van Hoof, Dirk Heerwegh, Erica N. Borducchi, Makda S. Gebre, Lauren Peter, Tatenda Makoni, Ahmed Abdul Azim
Publikováno v:
JAMA
Importance Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the ki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c08377b16842fb53684d63f63c34e97
https://europepmc.org/articles/PMC7953339/
https://europepmc.org/articles/PMC7953339/
Autor:
Maria Rowena Del Rosario-Raymundo, Gary Dubin, Céline Bouchard, Jorge Salmerón, Margaret E. Cruickshank, Frank Struyf, Tanya Stoney, Shelly A. McNeil, Xavier Castellsagué, Marie Cecile Bozonnat, Alison Fiander, Galina Minkina, Bram ter Harmsel, Alevtina Savicheva, Suzanne M. Garland, Deborah Money, Arunachalam Ilancheran, Mark G. Martens, Carlos S. Vallejos, Dominique Rosillon, Timothy Yong Kuei Lim, Kah Leng Fong, Cosette M. Wheeler, S R Skinner, Eduardo Lazcano-Ponce, Laurence Baril, Archana Chatterjee, Swee Chong Quek
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 10, Pp 4938-4953 (2019)
Cancer Medicine, Vol 8, Iss 10, Pp 4938-4953 (2019)
Background Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti‐HPV antibodies is uncertain. We examined the risk of HPV infections as def